TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00176605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
Study: NCT04272684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving Assessment
Description: Participants will undergo a driving assessment approximately two months after returning home from hospital
Study: NCT01321710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Description: This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Description: This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary information
Description: This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
Study: NCT03709238

Intervention type: BEHAVIORAL
Intervention: Thermal stimulation
Description: Thermal stimulation

Intervention type: BEHAVIORAL
Intervention: Thermal stimulation
Description: Thermal stimulation
Study: NCT01227187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa activated (Xigris)
Description: We will test different dose regimens of Drotrecogin alfa activated (Xigris) to determine the optimal dose to achieve PTT between 65 and 100 secs. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via pre-filter arterial drip chamber via a standard IV pump. The PTT will be assessed at baseline,15,30,60,120 and 180 mins. Xigris dose will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains \<65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
Study: NCT01097746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT02829307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-GSK3128349 1 mg
Description: 89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
Study: NCT00066703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin
Study: NCT03670212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine Hydrochloride
Description: 54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Monohydrate Powder
Description: Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
Study: NCT03553043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Energy label condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Energy label condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Energy label condition.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No label
Study: NCT00350051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (ZK 219477) + prednisone
Description: Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
Study: NCT03269071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human fetal-derived Neural Stem Cells (hNSCs)
Description: The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human fetal-derived Neural Stem Cells (hNSCs)
Description: The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human fetal-derived Neural Stem Cells (hNSCs)
Description: The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human fetal-derived Neural Stem Cells (hNSCs)
Description: The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture.
Study: NCT04117464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation therapy
Description: Behavioral activation therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Cognitive-Behavioral Therapy on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait List Group
Description: No psychological intervention
Study: NCT03113500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT02732769

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GammaKnifePerfexion®
Description: neurosurgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaKnifeIcon®
Description: neurosurgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efficast®
Description: Thermoformed mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT04066582

Intervention type: DEVICE
Intervention: ApolloVue™ S100 image system, Viper1-S003
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
Study: NCT01652183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous paracetamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02034890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
Study: NCT02363140

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Will undergo a single MRI assessment with intravenous dye

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Will undergo a single MRI assessment with intravenous dye

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pre and post surgery MRI scan
Study: NCT03687151

Intervention type: OTHER
Intervention: non intervention / observationnal
Description: non intervention / observationnal
Study: NCT01692964

Intervention type: DEVICE
Intervention: InflammaDry
Description: A noninvasive immunoassay for detecting MMP-9 levels in tears.
Study: NCT03825874

Intervention type: OTHER
Intervention: Amikacin
Description: A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.

Intervention type: OTHER
Intervention: usual antibiotic treatment
Description: A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
Study: NCT03024489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dose Level -1: 100 mg oral every other day 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dose Level 1: 75 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dose Level 2: 100 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dose Level 3: 125 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: All dose levels: 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: 5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
Study: NCT00094770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin (MK0431)
Description: Sitagliptin 100 mg oral tablets of sitagliptin once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: glipizide
Description: Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
Study: NCT05995288

Intervention type: DRUG
Intervention: Homeopathic Globule
Description: Homeopathic globules were administered after careful anamnesis
Study: NCT02936427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: perineural infiltration of dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: perineural infiltration of dexamethasone
Study: NCT01230242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine Device
Description: levonorgestrel intrauterine device insertion within ten minutes of placental delivery using a ring forceps insertion protocol
Study: NCT03002584

Intervention type: OTHER
Intervention: completion of self-reported questionnaires
Description: Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale
Study: NCT03943875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine, 2 dose efficacy
Description: Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine, 2 dose efficacy
Description: Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9-valent HPV vaccine, 3 doses standard timing
Description: Will be comparison group for 2 dose efficacy group.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9-valent HPV vaccine, 3 doses standard timing
Description: Will be comparison group for 2 dose efficacy group.
Study: NCT01601028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
Study: NCT02909075

Intervention type: DEVICE
Intervention: PET/CT scans

Intervention type: DEVICE
Intervention: MRI
Study: NCT02234284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Patient COPD education; Correct use of inhalers and nebulizers; Red flags and when to seek medical care; Dyspnea management; Patient decision making and action plans around, exercise, smoking cessation; nutrition, exacerbations; Ensuring appropriate preventive services (pneumovax, flu); Depression screening; Reinforcing clinician education and use of treatment guidelines by primary care providers; Identifying gaps in care, areas where care not in line with care plan; Facilitating communication between patients, pulmonary specialists and primary care providers; Connecting with community resources; Access to psychosocial services; Working with pulmonary specialist to provide recommended exercise program; Working with patient family members and caregivers.
Study: NCT00381342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
Study: NCT04659265

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suspected diagnosis of a pre-treating physician
Description: Participants receive the information that the pre-treating physician thought the patient is suffering from a medical emergency (no diagnosis), an acute myocardial infarction (correct diagnosis) or a pulmonary embolism (wrong diagnosis)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suspected diagnosis of a pre-treating physician
Description: Participants receive the information that the pre-treating physician thought the patient is suffering from a medical emergency (no diagnosis), an acute myocardial infarction (correct diagnosis) or a pulmonary embolism (wrong diagnosis)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suspected diagnosis of a pre-treating physician
Description: Participants receive the information that the pre-treating physician thought the patient is suffering from a medical emergency (no diagnosis), an acute myocardial infarction (correct diagnosis) or a pulmonary embolism (wrong diagnosis)
Study: NCT04729036

Intervention type: PROCEDURE
Intervention: open reduction and internal fixation
Description: The same surgical team have treated all the patients through open reduction via an intra-oral mucosal flap under general anesthesia with insertion and fixation of a 4-6 holes 2.0 miniplate and 5 mm screws at the superior border of the mandible at Champy's osteosynthesis line
Study: NCT01394042

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Proxiscan device
Description: All patients will be imaged with the device
Study: NCT00573430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Description: 8 mg oral once daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Description: 16 mg oral once daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 32mg
Description: 32 mg oral once daily dose
Study: NCT01918007

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillectomy (AT)
Description: Standard surgical intervention for treatment of obstructive sleep-disordered (SDB).
Study: NCT02838498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP Mechanical Simulator (EMS)
Description: Hands on EMS training
Study: NCT02598843

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment protocol
Description: Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB); 2 weeks FWB out of cast, with shoe insert heel raise.~Followed by course of physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Rehabilitation
Description: 4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance; 2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance; 2 weeks in Rebound walking boot with foot in neutral. At 8 weeks, remove boot and allow FWB out of boot.~At 8 weeks after initiation of treatment, physiotherapy is commenced.
Study: NCT03420690

Intervention type: OTHER
Intervention: satisfaction questionnaire after art therapy session
Description: After the administration of art therapy sessions (\>1) and the death of patients (\> 1 month), the intervention consists in submitting to families of patients a satisfaction questionnaire intended to evaluate the impact of art therapy session and in particular about their relationships.
Study: NCT04174781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg iv Q3W D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Description: DEB-TACE(epirubicin 60mg) D1; Additional DEB-TACE procedures were carried out every 4-6 weeks based on tumor response. A treatment cycle was defined as one DEB-TACE procedure plus two doses of sintilimab. The combination of DEB-TACE and sintilimab was continued for a maximum of 3 cycles until surgical resection, radiologic disease progression, unacceptable toxicity, or withdrawal from the study, whichever occurred first.
Study: NCT01255527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day
Study: NCT00556452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine/Busulfan x 4
Description: Clofarabine IV (dose levels)~* 1st dose level: 20 mg/m2/day x 5 days~* 2nd dose level: 30 mg/m2/day x 5 days~* 3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplant
Description: Peripheral blood stem cell transplant, after pre-conditioning drug treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation
Description: Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
Study: NCT02560376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-exendin-4
Description: 68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
Study: NCT01505621

Intervention type: OTHER
Intervention: L[ring-13C6]phenylalanine
Description: Oral drink composed of essential amino acids including L\[ring-13C6\]phenylalanine

Intervention type: OTHER
Intervention: L[ring-13C6]phenylalanine
Description: Oral drink composed of essential amino acids including L\[ring-13C6\]phenylalanine